By leveraging the largest cancer patient cohort described to-date, the data provide clarity relative to previous reports on the frequency and characteristics of patients with biallelic, clear loss-of-function (truncating) mutations in SMARCA4 that are potential candidates for future SMARCA2-targeting therapies. This evidence concerns the gene SMARCA4 and cancer.